argenx (ADR) (ARGX)
Develops antibody medicines for severe autoimmune diseases around the VYVGART franchise.
Something off on this page? Send us feedback.
Develops and commercializes antibody medicines for severe autoimmune diseases, centered on VYVGART. The same efgartigimod medicine spans three approved indications, while academic co-creation and in-house antibody engineering feed additional candidates.
Develops antibody medicines for severe autoimmune diseases through the VYVGART franchise and an earlier-stage pipeline. VYVGART and VYVGART HYTRULO use efgartigimod, an FcRn blocker approved across generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia in Japan.
The business has expanded from European research roots into a global commercial immunology operation, with launches in the United States, Japan, and Europe. Its Immunology Innovation Program pairs academic disease biologists with in-house antibody engineers, supported by the SIMPLE ANTIBODY discovery platform and Fc-engineering technologies.
Commercial performance remains anchored in efgartigimod. Additional growth depends on successful clinical and regulatory expansion into new indications and on advancing candidates such as empasiprubart; prior studies have produced both successful evidence and missed endpoints.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 31, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $1,230 | Target: $1,250 |
| Aug 26, 2026 | Wells Fargo | Reiterate | Rating: —Target: $1,350 | Target: $1,415 |
| Aug 26, 2026 | UBS | Upgrade | Target: $910 | Target: $1,400 |
| Aug 24, 2026 | Deutsche Bank | Downgrade | ||
| Aug 18, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $1,200 | Target: $1,230 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.18B · Total debt $47.0M · Total assets $10.03B · Shareholders' equity $8.42B
- Revenue
- $2.82B
- Operating income
- $846.8M
- Net income
- $838.8M
No dividends on record.
| Institutions | 45.65% | 28.25M ADS | |
|---|---|---|---|
| 527 holders · as of Jun 30, 2026 | |||
| Other | 54.35% | 33.63M ADS | |
| remainder | |||
61.88M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 8.45% | 5.23M ADS | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 4.33% | 2.68M ADS | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 4.00% | 2.47M ADS | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 3.55% | 2.20M ADS | as of Jun 30, 2026 |
Artisan Partners Limited PartnershipInstitution | 2.44% | 1.51M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Johnson & Johnson
FcRn-blocking rival across broad antibody-positive gMG populations
- AstraZeneca (ADR)
Established complement-inhibitor alternatives in gMG
- Takeda (ADR)
Subcutaneous immunoglobulin alternative in CIDP maintenance
- Amgen
CD19-targeted B-cell alternative for antibody-positive gMG
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| argenx (ADR) | $975.49 | −1.29% | $61.45B | 37.7 | — | 10.2 | +197.0% |
| Johnson & Johnson | $267.82 | −0.61% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| AstraZeneca (ADR) | $168.41 | +0.18% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Takeda (ADR) | $19.00 | +0.56% | $60.11B | 52.5 | 60.1 | 2.0 | +4.2% |
| Amgen | $407.59 | +3.67% | $212.19B | 24.4 | 17.4 | 5.6 | +9.7% |
| Median | 28.2 | 20.0 | 4.9 | +6.5% |